Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chart: Timeline Of Pharma Provisions In Health Care Reform

Executive Summary

It is arranged in seven sections, with provisions in each arranged chronologically. If the date is listed as "upon enactment," it means no date was specified in the statute; however, in many cases, regulatory agencies may need to issue guidance or regulations before the provision can be implemented. The information is based on the two health care reform bills: H.R. 3590, which contains the bulk of the reform language, passed the Senate in December, passed the House March 21, and was signed into law March 23; and subsequent fixes in the budget reconciliation bill, H.R. 4872, which cleared the House March 21 and Senate March 25, and the president was expected to sign March 30. The chart also borrows from a comparison chart of pharma provisionsin the two bills by Ian Spatz of Manatt, Phelps & Phillips.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS052070

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel